References
- Colombo AL, Guimarães T, Silva LR, . Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007;28:570–576.
- Wisplinghoff H, Bischoff T, Tallent SM, . Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–317.
- Costa SF, Marino I, Araujo EA, . Nosocomial fungaemia: a 2-year prospective study. J Hosp Infect 2000;45:69–72.
- Godoy P, Tiraboschi IN, Severo LC, . Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz 2003;98:401–405.
- Medrano DJ, Brilhante RS, Cordeiro R de A, . Candidemia in a Brazilian hospital: the importance of Candida parapsilosis. Rev Inst Med Trop Sao Paulo 2006;48:17–20.
- Giusiano G, Mangiaterra M, Saito VG, . Etiology of fungaemia and catheter colonization in Argentinean paediatric patients. Mycoses 2006;49:49–54.
- Matta VLR, Melhem MSC, Colombo AL, . Susceptibility profile to antifungal drugs of Pichia anomala isolated from patients presenting nosocomial fungemia. Antimicrob Agents Chemother 2007;51:1573–1576.
- Pfaller MA, Messer SA; Hollis R, . Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999;33:217–222.
- Da Matta DA, Machado AM, Azevedo AC, . Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995– 2003. Diagn Microbiol Infect Dis 2007;57:399–404.
- Cuenca-Estrella M, Rodriguez-Tudela JL, . Red regional de laboratorios para la vigilancia de las infecciones fúngicas invasoras y susceptibilidad a los antifúngicos. Pan Amer J Pub Heal 2008;23:129–134.
- EUCAST-The European Committee on Antimicrobial Susceptibility Testing. [Updated 16 April 2009]. Available from: <http://www.eucast.org>.
- Dannaoui E, Paugam A, Develoux M, . Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories Clin Microbiol Infect 2009; Sep 23. [Epub ahead of print].
- Pasqualotto AC, Nedel WL, Machado TS, Severo L. A 9-year study comparing risk factors and the outcome of paediatric and adults with nosocomial candidaemia. Mycopathologia 2005;160:111–116.
- Horn DL, Neofytos D, Anaissie EJ, . Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48:1695–1703.
- Gomez-Lopez A, Pan D, Cuesta I, . Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagn Microbiol Infect Dis 2009 [Epub].
- Milici ME, Maida CM, Spreghini E, . Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. J Clin Microbiol 2007;45:3529–3533.
- Playford EG, Marriott D, Nguyen Q, . Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008;7:2034–2039.
- Bassetti M, Trecarichi EM, Righi E, . Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007;3:325–331.
- Brito LR, Guimaraes T, Nucci M, . Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med Mycol 2006;44:261–266.
- Miranda LN, van der Heijden IM, Costa SF, . Candida colonisation as a source for candidaemia. J Hosp Infect 2009;72:9–16.
- Tay ST, Na SL, Chong J. Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J Med Microbiol 2009;58:185–191.
- Lin D, Wu LC, Rinaldi MG, . Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol 1995;33:1815–1821.
- Tavanti A, Davidson AD, Gow NA, . Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005;43:284–292.
- van Asbeck E, Clemons KV, Martinez M, . Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008;62:106–109.
- Goldani LZ, Mario PS. Candida tropicalis fungemia in a tertiary care hospital. J Infect 2003;46:155–160.